Asset
IMAPRELIMAB
Prothena Corporation plc Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02630901 | phase1 | completed | 2016-03-17 | 2018-02-28 | Prothena Biosciences Limited | Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis |
| NCT02458677 | phase1 | completed | 2015-05-01 | 2016-02-01 | Prothena Biosciences Limited | Single Ascending Dose Study of PRX003 in Healthy Subjects |
FDA applications (0)
This company has no applications containing this asset.